ABS-201 in Androgenetic Alopecia

Trial
100%50%0%Jun 25Jun 26Jun 27Jun 28Jun 29Jun 30Jul 1Jul 2Jul 3Jul 4Jul 5Jul 6Jul 7Jul 8Jul 9Jul 10Jul 11Jul 12Jul 13Jul 14Jul 15Jul 16Jul 17Jun 25 • YES 31.9%Jun 29 • YES 32.9%Jun 30 • YES 32.9%Jul 1 • YES 100.0%Jul 2 • YES 48.4%Jul 3 • YES 93.5%Jul 4 • YES 93.5%Jul 5 • YES 93.5%Jul 6 • YES 94.4%Jul 7 • YES 2.7%Jul 8 • YES 99.8%Jul 9 • YES 6.8%Jul 10 • YES 100.0%Jul 17 • YES 99.9%
Stock ($ABSI)Daily close · through Jul 17
No stock close$11.99$9.85$7.71Jun 25Jun 26Jun 27Jun 28Jun 29Jun 30Jul 1Jul 2Jul 3Jul 4Jul 5Jul 6Jul 7Jul 8Jul 9Jul 10Jul 11Jul 12Jul 13Jul 14Jul 15Jul 16Jul 17Jul 9 • ABSI $11.47Jul 10 • ABSI $10.60Jul 13 • ABSI $10.21Jul 14 • ABSI $10.23Jul 15 • ABSI $9.76Jul 16 • ABSI $8.23Jul 17 • ABSI $8.30

Will Absci report a numerical improvement in Target Area Hair Count (TAHC) for ABS-201 in AGA patients by Dec. 31, 2026?

Create account to trade
NO DECISIONDismissed84% confidenceGPT-5.6 Sol (OpenAI)
Question
Will Absci report a numerical improvement in Target Area Hair Count (TAHC) for ABS-201 in AGA patients by Dec. 31, 2026?
Found
Reviewed
Summary

Absci’s June 24, 2026 readout is positive for interim Phase 1 safety/PK/immunogenicity, but it does not report numerical TAHC improvement. It says AGA MAD has just begun and proof-of-concept data are expected later, so the market endpoint remains unresolved.

Sources
Sponsorabsci.gcs-web.com
Absci Announces Positive Interim Phase 1 Data from the HEADLINE Trial of ABS-201

Positive interim data were safety/PK-focused; AGA MAD had initiated, TAHC is a secondary endpoint, and interim proof-of-concept data are anticipated in H2 2026.

Stats
Latest Run
Model
GPT-5.6 Sol (OpenAI)
Runs
1 run